{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:17:11Z","timestamp":1784027831100,"version":"3.55.0"},"reference-count":24,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>Antitumour necrosis factor alpha agents are important treatments in many inflammatory conditions including rheumatoid arthritis, psoriatic arthritis and the inflammatory bowel diseases. However, there have been case reports of optic neuritis and other demyelinating diseases as complications of these agents. This case report presents a patient with ulcerative colitis on infliximab who presented with sudden onset mono-ocular visual field loss and highlights the diagnosis and management of infliximab-induced optic neuritis.<\/jats:p>","DOI":"10.1136\/bcr-2020-236041","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T18:18:21Z","timestamp":1608661101000},"page":"e236041","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Infliximab-induced optic neuritis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0172-7872","authenticated-orcid":false,"given":"Andrew","family":"Dermawan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"So","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kannan","family":"Venugopal","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5013-956X","authenticated-orcid":false,"given":"Sherman","family":"Picardo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Perth Hospital, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"2025082801580000000_13.12.e236041.1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw003"},{"key":"2025082801580000000_13.12.e236041.2","doi-asserted-by":"publisher","DOI":"10.1159\/000140257"},{"key":"2025082801580000000_13.12.e236041.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.09.002"},{"key":"2025082801580000000_13.12.e236041.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.01.012"},{"key":"2025082801580000000_13.12.e236041.5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bpg.2018.05.005","article-title":"Safety of biological therapies in ulcerative colitis: an umbrella review of meta-analyses","volume":"32-33","author":"Bonovas","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2025082801580000000_13.12.e236041.6","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1145653"},{"key":"2025082801580000000_13.12.e236041.7","first-page":"1","article-title":"Bilateral optic neuritis associated with the use of infliximab","volume":"2011","author":"Aasly","year":"2011","journal-title":"Case Rep Ophthalmol Med"},{"key":"2025082801580000000_13.12.e236041.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7389.579"},{"key":"2025082801580000000_13.12.e236041.9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jns.12147","article-title":"Anti-Tnf alpha medications and neuropathy","volume":"20","author":"Tsouni","year":"2015","journal-title":"J Peripher Nerv Syst"},{"key":"2025082801580000000_13.12.e236041.10","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2010.495814"},{"key":"2025082801580000000_13.12.e236041.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202273260901"},{"key":"2025082801580000000_13.12.e236041.12","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab","volume":"120","author":"Foroozan","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"2025082801580000000_13.12.e236041.13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.457"},{"key":"2025082801580000000_13.12.e236041.14","unstructured":"Osborne B , Balcer L . Optic neuritis: pathophysiology, clinical features and diagnosis. UpToDate, 2018."},{"key":"2025082801580000000_13.12.e236041.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp053247"},{"key":"2025082801580000000_13.12.e236041.16","unstructured":"Wray SH . Optic neuritis. In: Albert DM , Jakobiec FA , eds. Principles and practice of ophthalmology. Philadelphia: WB Saunders, 1994: 2539."},{"key":"2025082801580000000_13.12.e236041.17","doi-asserted-by":"publisher","DOI":"10.1080\/08820530390895172"},{"key":"2025082801580000000_13.12.e236041.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410315"},{"key":"2025082801580000000_13.12.e236041.19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/110.2.405"},{"key":"2025082801580000000_13.12.e236041.20","unstructured":"Osborne B , Balcer L . Optic neuritis: prognosis and treatment. UpToDate, 2018."},{"key":"2025082801580000000_13.12.e236041.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.11.1514"},{"key":"2025082801580000000_13.12.e236041.22","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000152873.82631.B3"},{"key":"2025082801580000000_13.12.e236041.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2008.02258.x"},{"key":"2025082801580000000_13.12.e236041.24","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000138437.99046.6B"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-236041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:58:09Z","timestamp":1756371489000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-236041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,22]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-236041"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-236041","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}